The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1744
December 22, 2025
View Complete Issue         Table of Contents 2019 
Nerandomilast (Jascayd) for Idiopathic Pulmonary Fibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nerandomilast (Jascayd) for Idiopathic Pulmonary Fibrosis
December 22, 2025 (Issue: 1744)
Nerandomilast (Jascayd – Boehringer Ingelheim), an oral phosphodiesterase 4 (PDE4) inhibitor, has been approved by the FDA for treatment of idiopathic pulmonary fibrosis (IPF) in adults. It is the third drug to be approved in the US for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nerandomilast (Jascayd) for Idiopathic Pulmonary Fibrosis
Article code: 1744d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.